Earnings Call Insights: Bionano Genomics (BNGO) Q4 2024 Management View CEO Erik Holmlin highlighted a strategic shift toward optimizing the utilization of existing optical genome mapping (OGM ...

Bionano Genomics (NASDAQ:BNGO) expects revenue for the Q3 of 2024 to be between $6.5 and $6.8M vs. consensus of $7.85M, down from prior guidance of between $7.9 and $8.9M. Cash, equivalents ...

That’s particularly true for Bionano Genomics because it has changed in important ways. Most notably, the meteoric rise of BNGO stock has cleaned up the company’s balance sheet.

Bionano Genomics stock has had a rough 12 months. But its business model is still attractive due to its long-term recurring revenue potential. Developing new consumables and new devices will also ...

Bionano Genomics (NASDAQ:BNGO) is preparing to release its quarterly earnings on Wednesday, 2025-05-14. Here's a brief overview of what investors should keep in mind before the announcement ...

View Bionano Genomics, Inc. BNGO stock quote prices, financial information, real-time forecasts, and company news from CNN.

Bionano Genomics, Inc (BNGO 1.84%) Q3 2022 Earnings Call Nov 03, 2022, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, and ...

Bionano benefits from strong sector tailwinds and equity inflows to the genomics sector where growth has outpaced the broader market in recent years.

Bionano Genomics is an engaging company operating in the genome mapping space. Check out what makes BNGO a lukewarm buy opportunity at best for the time being.

--Bionano Genomics, Inc. today reported financial results and business achievements for the fourth quarter and year ended December 31, 2020 and highlighted recent corporate updates. We believe ...